AstraZeneca

Showing 15 posts of 785 posts found.

astrazeneca_sign_sky

AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

June 22, 2018
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …

nerve-cell-2213009_960_720

Another failure in Alzheimer’s creates bleak outlook for treatment

June 12, 2018
Manufacturing and Production, Research and Development Alzheimer's, AstraZeneca, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …

astrazeneca_logo_building

EU gives nod to expanded label for AZ’s Tagrisso

June 11, 2018
Sales and Marketing AstraZeneca, Tagrisso, biotech, drugs, pharma, pharmaceutical

AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line …

astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

astrazeneca-sign

AZ’s hopes for Fasenra in COPD suffer terminal blow

May 30, 2018
Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical

It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …

AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer

May 25, 2018
Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

astrazeneca_sign_sky

FDA approves AZ’s Lokelma for hyperkalaemia

May 21, 2018
Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma

The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …

top_ten

Top Ten most popular articles on Pharmafile.com this week

May 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

AZ’s Fasenra stumbles in P3 for COPD

May 11, 2018
Medical Communications, Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical

AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …

credit_-_daniel_leal-olivas-afp

European approval for tablet formulation of Lynparza in ovarian cancer

May 8, 2018
Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …

astrazeneca_sign_sky

AstraZeneca jettisons schizophrenia drug for $538 million

May 8, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …

astrazeneca_logo_building

AZ’s combo woes continue, with failure in lung cancer

April 24, 2018
Manufacturing and Production, Research and Development AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical

AstraZeneca has been hit by a fresh blow in its search for an immunotherapy combination treatment that could differentiate it …

astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

shutterstock_79370437

Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso

April 13, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …

The Gateway to Local Adoption Series

Latest content